News

March 21, 2011 - OrbusNeich today announced it filed a lawsuit in the Netherlands against a doctor and principal investigator of a trial examining OrbusNeich's Genous coronary stent.

February 21, 2011 – Two drug-eluting coronary stent systems have been launched in India. Boston Scientific’s Promus Element everolimus-eluting stent system and Taxus Element paclitaxel-eluting...

February 21, 2011 – The first patient has been enrolled the DESSOLVE II study to support CE mark for a coronary stent that uses a bioresorbable drug polymer. The MiStent drug-eluting coronary...

January 26, 2011 – Patient enrollment has begun in China for a trial evaluating the safety and effectiveness of a next-generation stent. The PLATINUM China clinical trial will look at the Promus...

January 24, 2011 – Patient enrollment was completed in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Boston Scientific's fourth-generation Synergy...

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime everolimus-eluting coronary stent for the treatment of critical limb ischemia (CLI) or...

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...

December 6, 2010 - A European court has struck a blow to Boston Scientific's alleged patent infringement case against OrbusNeich. The case is viewed by OrbusNeich as an unsuccessful retaliatory...

September 28, 2010 – Three-year follow-up data from the HORIZONS-AMI trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2010 last week continues to show marked improvement of...

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in the femoropopliteal artery. Data from the ZILVER PTX trial demonstrate that...

September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when...

September 23, 2010 - Results from the second stage of a trial studying a bioresorbable vascular scaffold were announced at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington...

September 23, 2010 - Results from a study evaluating the safety and clinical efficacy of the Promus Element everolimus-eluting coronary stent will be released at the Transcatheter Cardiovascular...

September 22, 2010 – Coronary artery disease, a leading cause of death and poor quality of life worldwide, can often complicate the daily practice of interventional cardiology. But new data from...

September 21, 2010 – A new drug-eluting stent system has received CE mark approval for diabetic patients and those experiencing a heart attack.

The PROMUS element everolimus-eluting stent...

September 20, 2010 – Patient enrollment has started in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir Medical’s novolimus-eluting coronary stent with bioabsorbable coating,...

September 14, 2010 – The latest clinical trial data for the Promus Element and Taxus Element coronary stents will be released during the Transcatheter Cardiovascular Therapeutics (TCT) scientific...

September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided...

September 7, 2010 – New analyses of subgroups from the SORT OUT III study provide detail on longer-term follow-up safety and efficacy outcomes in diabetics and patients with acute coronary...

September 1, 2010 - The results of follow-up tests undertaken ten years after the first patient was treated with a Cypher sirolimus-eluting coronary stent were presented at the European Society of...